Cover Image
Market Research Report

Onychomycosis - Market Insights, Epidemiology and Market Forecast - 2030

Published by DelveInsight Business Research LLP Product code 773931
Published Content info 75 Pages
Delivery time: 1-2 business days
Price
Back to Top
Onychomycosis - Market Insights, Epidemiology and Market Forecast - 2030
Published: May 1, 2020 Content info: 75 Pages
Description

DelveInsight's 'Onychomycosis- Market Insights, Epidemiology and Market Forecast-2030 report delivers an in-depth understanding of the disease, historical &forecasted epidemiology as well as the market trends of Onychomycosis in the United States.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Onychomycosis from 2017 to 2030 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered:

  • The United States

Study Period: 2017-2030

Onychomycosis- Disease Understanding and Treatment Algorithm

Onychomycosis, a fungal infection of the nail, is the most common nail infection worldwide, causing discoloration and thickening of the affected nail plate. Onychomycosis was initially thought to be caused by dermatophytes predominantly; however, new research has revealed that mixed infections and those caused by nondermatophyte molds (NDMs) are more prevalent than thought previously, especially in warmer climates.

Several treatment options are available for treating Onychomycosis, including oral antifungals, topical antifungals, and devices. Oral antifungals have higher for treatment cure rates and shorter treatment periods than topical treatments, but have adverse side effects such as hepatotoxicity and drug interactions. Terbinafine, itraconazole, and fluconazole are the most commonly used antifungals, Topical treatments, such as efinaconazole, tavaborole, ciclopirox, and amorolfine, have less serious side effects but result in lower cure rates generally and much longer treatment regimens. New topical formulations are being investigated as faster-acting alternatives to the currently available topical treatments.

The DelveInsight Onychomycosis market report gives the thorough understanding of Onychomycosis by including details such as disease definition, classification, symptoms, etiology and risk factors, pathophysiology, disease progression and diagnostic trends.

Onychomycosis Epidemiology

The Onychomycosis epidemiology division provide the insights about historical and current patient pool and forecasted trend for the United States. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Diagnosed prevalent cases of Onychomycosis, Prevalent cases of Onychomycosis by subtype, Prevalence of Onychomycosis by Severity) scenario of Onychomycosis in the United States from 2017-2030.

According to DelveInsight, the total number of prevalent cases of Onychomycosisin the US was found to be 3,58,29,110 in the year 2017.

Onychomycosis Drug Chapters

This segment of the Onychomycosis report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details and the latest news and press releases.

Currently the primary treatment for onychomycosis can be divided into components based on routes of administration namely; Systemic (Oral) and Topical Medications. Challenges of targeted drug delivery and limited side effects are two factors which are going to decide the fate of all the pipeline therapies.

Onychomycosis Market Outlook

The Onychomycosismarket outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of Athlete's foot in 7MM was found to be USD 2,095 million in 2017, and is expected to increase during the course of the study period (2017-2030).

Onychomycosis Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2030. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Onychomycosis Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Onychomycosis Report Key Strengths

  • 11 Year Forecast
  • The US Coverage
  • Epidemiology Segmentation
  • Key Cross Competition
  • Market size by therapies
  • Drugs Uptake

Onychomycosis Report Assessment

  • Detailed Pipeline Product Profiles
  • Key products and key players
  • Market Drivers and Barriers

Key Benefits:

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Onychomycosis market
  • Organize sales and marketing efforts by identifying the best opportunities for Onychomycosis market
  • To understand the future market competition in the Onychomycosis market.
Table of Contents
Product Code: DIMI0447a

Table of Contents

1. Key Insights

2. Executive Summary of Onychomycosis

3. SWOT Analysis for Onychomycosis

4. Disease Background and Overview

  • 4.1. Introduction
  • 4.2. Etiology and Risk factors
  • 4.3. Pathophysiology
  • 4.4. Types
  • 4.5. Clinical Aspects
  • 4.6. Clinical Presentation and Diagnosis

5. Epidemiology and Patient Population - The United States

  • 5.1. Key Findings
  • 5.2. Assumptions and rationale
    • 5.2.1. Diagnosed prevalent cases of Onychomycosis
    • 5.2.2. Prevalent cases of Onychomycosis by subtype
    • 5.2.3. Prevalence of Onychomycosis by Severity

6. Treatment and Management

  • 6.1. Treatment Algorithm
  • 6.2. Management of Onychomycosis

7. Patient Journey

8. Unmet Needs

9. Case Study

  • 9.1. Case Report of Onychomycosis and Tinea Corporis Due to Microsporum gypseum

10. Marketed Therapies

  • 10.1. Kerydin (tavaborole): Pfizer
    • 10.1.1. Product Description
    • 10.1.2. Product Development Activities
    • 10.1.3. Clinical Development
    • 10.1.4. Safety and Efficacy
  • 10.2. Jublia (efinaconazole): Bausch Health
    • 10.2.1. Product Description
    • 10.2.2. Product Development Activities
    • 10.2.3. Clinical Development
    • 10.2.4. Safety and Efficacy

11. Emerging Therapies

  • 11.1. MOB015: Moberg Pharma
    • 11.1.1. Product Description
    • 11.1.2. Product Development Activities
    • 11.1.3. Clinical Development
    • 11.1.4. Clinical trials information
    • 11.1.5. Safety and Efficacy
  • 11.2. BB2603: Blueberry Therapeutics
    • 11.2.1. Product Description
    • 11.2.2. Other Developmental Activities
    • 11.2.3. Clinical Development
  • 11.3. VT-1161: Mycovia Pharmaceuticals
    • 11.3.1. Product Description
    • 11.3.2. Other Developmental Activities
    • 11.3.3. Clinical Development
    • 11.3.4. Safety and Efficacy

12. Other Promising Candidates

  • 12.1. ME1111: Meiji Seika Pharma
    • 12.1.1. Product Description
    • 12.1.2. Clinical Development
  • 12.2. NP213 (Novexatin): NovaBiotics
    • 12.2.1. Product Description
    • 12.2.2. Other Developmental Activities
    • 12.2.3. Clinical Development
  • 12.3. HTS-519: Hallux
    • 12.3.1. Product Description
    • 12.3.2. Clinical Development

13. Discontinued Products

  • 13.1. P3058: Almirall
    • 13.1.1. Product Description
    • 13.1.2. Product Development Activities
    • 13.1.3. Clinical Development

14. Onychomycosis: The United States Market Analysis

  • 14.1. Key Findings
  • 14.2. Market Outlook [the United States]
  • 14.3. The United States Market Size
    • 14.3.1. Total Market size of Onychomycosis
    • 14.3.2. Onychomycosis Market Size by Therapies

15. Market Drivers

16. Market Barriers

17. Appendix

  • 17.1. Report Methodology

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

List of Tables

  • Table 1: Summary of Onychomycosis Market, Epidemiology, and Key Events (2017-2030)
  • Table 2: Risk factors
  • Table 3: Diagnosed Prevalent Cases of Onychomycosis in the United States (2017-2030)
  • Table 4: Prevalent Cases of Onychomycosis by subtype in the United States (2017-2030)
  • Table 5: Prevalence of Onychomycosis by Severity in the United States (2017-2030)
  • Table 6: MOB015, Clinical Trial Description, 2020
  • Table 7: BB2603, Clinical Trial Description, 2020
  • Table 8: VT-1161, Clinical Trial Description, 2020
  • Table 9: The US Market size of Onychomycosis in USD Million (2017-2030)
  • Table 10: The US market size of Onychomycosis by Therapies in USD Million (2017-2030)

List of Figures

  • Figure 1: SWOT Analysis
  • Figure 2: Diagnosed prevalent cases of Onychomycosis in the United States (2017-2030)
  • Figure 3: Prevalent Cases of Onychomycosis by subtype in the United States (2017-2030)
  • Figure 4: Prevalence of Onychomycosis by Severity in the United States (2017-2030)
  • Figure 5: Market Size of Onychomycosis in the United States, USD Millions (2017-2030)
  • Figure 6: The U.S. market size of Onychomycosis by therapies in USD Million (2017-2030)
  • Figure 7: Market Drivers
  • Figure 8: Market Barriers
Back to Top